PI3K/Akt/mTOR-IN-2
CAS No. 2757804-89-8
PI3K/Akt/mTOR-IN-2( —— )
Catalog No. M35442 CAS No. 2757804-89-8
PI3K/Akt/mTOR-IN-2 is a potent PI3K/AKT/mTOR inhibitor with anticancer effects and selectivity for MDA-MB-231 cells (IC50 2.29 μM). It induces cell cycle arrest and apoptosis in cancer cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 50 | Get Quote |
|
| 5MG | 72 | Get Quote |
|
| 10MG | 126 | Get Quote |
|
| 25MG | 260 | Get Quote |
|
| 50MG | 419 | Get Quote |
|
| 100MG | 602 | Get Quote |
|
| 500MG | 1278 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePI3K/Akt/mTOR-IN-2
-
NoteResearch use only, not for human use.
-
Brief DescriptionPI3K/Akt/mTOR-IN-2 is a potent PI3K/AKT/mTOR inhibitor with anticancer effects and selectivity for MDA-MB-231 cells (IC50 2.29 μM). It induces cell cycle arrest and apoptosis in cancer cells.
-
DescriptionPI3K/Akt/mTOR-IN-2 is a PI3K/AKT/mTOR pathway inhibitor. PI3K/Akt/mTOR-IN-2 possess anti-cancer effects and selectivity against MDA-MB-231 cells with IC50 value of 2.29 μM. PI3K/Akt/mTOR-IN-2 can induce cancer cell cycle arrest and apoptosis.
-
In VitroPI3K/Akt/mTOR-IN-2 (compound 23) (0.5 - 100 μM; 72 hours) exhibits effective anti-cancer activity with IC50s of 2.29 - 24.63 μM, of which, IC50 in MDA-MB-231 is 2.29 μM.PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 24 hours) induces growth inhibition of MDA-MB-231 cells by cell cycle arrest at G0/G1.PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 24, 48 and 72 hours) induces apoptosis in MDA-MB-231 cells with both dose- and time-dependent manners.PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 48 hours) increases the expression of Bax, and decreases the expression of Bcl-2 in MDA-MB-231 cells.PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 24 hours) induces mitochondria-dependent apoptosis in MDA-MB-231 cells through disruption of MMP, accumulation of ROS, depletion of GSH and elevation of intracellular Ca2+.]Cell Proliferation Assay Cell Line:PC3, BGC-823, A549, MCF-7, MDA-MB-231 cells and MCF-10A cells Concentration:0.5 - 100 μMIncubation Time:72 hoursResult:Exhibited effective anti-cancer activity with IC50s of 2.29 - 24.63 μM, of which, IC50 in MDA-MB-231 was 2.29 μM.Cell Cycle Analysis Cell Line:MDA-MB-231 Concentration:1 μM, 2 μM and 4 μM Incubation Time:24 hours Result:Induced growth inhibition of MDA-MB-231 cells by cell cycle arrest at G0/G1. Apoptosis Analysis Cell Line:MDA-MB-231 Concentration:1 μM, 2 μM and 4 μM Incubation Time:24, 48 and 72 hours Result:Induced apoptosis in MDA-MB-231 cells with both dose- and time-dependent manners.Western Blot Analysis Cell Line:MDA-MB-231 Concentration:1 μM, 2 μM and 4 μM Incubation Time:48 hours Result:Increased the expression of Bax, and decreased the expression of Bcl-2
-
In Vivo——
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetmTOR
-
RecptormTOR | Akt | Apoptosis | PI3K
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2757804-89-8
-
Formula Weight285.29
-
Molecular FormulaC17H13F2NO
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 100 mg/mL (350.52 mM)
-
SMILESFc1cc(F)cc(c1)C1OCCc2c1[nH]c1ccccc21
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Qin J, Sun X, Ma Y, et al. Design, synthesis and biological evaluation of novel 1,3,4,9-tetrahydropyrano[3,4-b]indoles as potential treatment of triple negative breast cancer by suppressing PI3K/AKT/mTOR pathway [published online ahead of print, 2021 Dec ?
molnova catalog
related products
-
XL413 hydrochloride
XL-413 is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity.
-
CC-115 hydrochloride
A novel dual inhibitor of mTOR and DNA-PK with IC50 of 21 nM and 13 nM, respectively.
-
TMBIM6 antagonist-1
TMBIM6 antagonist-1 is an antagonist of TMBIM6.
Cart
sales@molnova.com